Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07674654 · ClinicalTrials.gov registry record · Phase 3
A Long-Term Safety Study of Elismetrep (K-304) in the Acute Treatment of Migraine
A Phase 3 study, sponsored by Kallyope.
- Not yet
- Registry status
- Phase 3
- Development phase
- 1,000
- Enrollment target
NCT07674654: Clinical Trial Phase 3 study, sponsored by Kallyope.
NCT07674654 is a Phase 3 study that has not yet begun recruiting, run by Kallyope. The registered enrollment target is 1,000 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07674654, a Phase 3 study, has not yet begun recruiting, sponsored by Kallyope.
- NOT YET RECRUITING
- Registry status
- Phase 3
- Development phase
- 1,000 participants
- Enrollment target
Study Summary
This is a long-term safety study to evaluate the safety and tolerability of intermittent use of elismetrep in the acute treatment of migraine attacks.
Interventions
- DRUG Placebo
- DRUG Elismetrep
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,000 participants |
| Start Date | 2026-07 |
| Est. Completion | 2028-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07674654
The ClinicalTrials.gov registry entry for NCT07674654 describes a study currently listed as not yet recruiting, categorized as Phase 3. The registered enrollment target is 1,000 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kallyope, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT07674654 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07674654 about?
NCT07674654 is a clinical study titled "A Long-Term Safety Study of Elismetrep (K-304) in the Acute Treatment of Migraine". This is a long-term safety study to evaluate the safety and tolerability of intermittent use of elismetrep in the acute treatment of migraine attacks.
What is the current status of trial NCT07674654?
This trial is currently not yet recruiting. It is a Phase 3 study. The enrollment target is 1,000 participants. The study started on 2026-07. Estimated completion is 2028-06.
What interventions are being tested in trial NCT07674654?
The interventions under investigation include: Placebo (DRUG), Elismetrep (DRUG).
Who is sponsoring clinical trial NCT07674654?
This trial is sponsored by Kallyope, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.